Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2175)	12/10/2000 10:07:11 PM
From: Spekulatius	Read Replies (1) \| Respond to of 4974

I doubt that a LEXG insider has been hit by a margin call.I have observed the washout pattern with an apparent total capitulation in a few biotech IPO stocks, namely LEXG, DCGN and to a lesser extend PRCS a few days ago. The above are all quality companies and those washout's great trading opportunities or a great entry point for the few remaining LT investors <g>.

To: scaram(o)uche who wrote (2175)	12/13/2000 11:40:50 AM
From: Elmer	Read Replies (3) \| Respond to of 4974

Hi Richard, The recent open interest on put options for MAXM, before yesterday's announcement, was much higher than that for calls telling me that a lot of people knew the data was manipulated. Are the FDA filings open to the public for review prior to the advisory board meeting? Curiously, Franklin Berger of J.P. Morgan and Rob Toth thought the odds favored approval. So, how is it that the Street knows knows the data stinks and the analysts don't? Thanks